Dymicron
Early Stage
Replace.Restore.Revitalize
Overview
Platform
Dealmaker Securities
Start Date
01/24/2023
Close Date
01/24/2024
Min. Goal
$1,001
Max. Goal
$15,824,560
Min. Investment
$1,001
Security Type
Equity - Common
Series
Series B
Funding Type
RegA+
Price Per Share
$5.75
Pre-Money Valuation
$28,820,535
Location
Orem, Utah
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
Dymicron is raising funds through Reg A+ crowdfunding with Dealmaker Securities as the Broker-Dealer. It is a medical device technology company making a new generation of musculoskeletal devices. The company uses its patented material, Polycrystalline Diamond, for its devices that can be used in all interbody applications. Dymicron’s first product, the Triadyme-C, is a cervical total disc replacement device made of PCD and able to replicate natural spinal motion. Alan S. Layton founded Dymicron in 1997. The current crowdfunding campaign has a maximum target of $15.8 million. The campaign proceeds will be used for clinical trials, FDA applications, commercialization of Triadyme-C in Europe, research and development, and general and administrative expenses.
Balance Sheet
|
Cash and Cash Equivalents |
$1,202,541 |
|
Accounts and Notes Receivable |
$40,741 |
|
Property, Plant and Equipment (PP&E) |
$385,028 |
| Total Assets |
$2,488,964 |
|
Accounts Payable & Accrued Liabilities |
$238,391 |
|
Long Term Debt |
$45,730,124 |
|
Total Liabilities |
$68,586,613 |
|
Total Stockholders' Equity |
$-66,097,649 |
| Total Liabilities and Equity |
$2,488,964 |
Statement of Comprehensive Income Information
|
Total Revenues |
$104,292 |
|
Costs & Expenses Applicable to Rev |
$49,831 |
|
Depreciation and Amortization |
$37,236 |
| Net Income |
$-4,084,223 |
|
Earnings Per Share - Basic |
$-0.09 |
|
Earnings Per Share - Diluted |
$-0.09 |
Financials as of: 01/24/2023
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Analyst Report 
Pending Review